Previous close | 19.31 |
Open | 19.37 |
Bid | 19.11 x 1300 |
Ask | 19.12 x 1300 |
Day's range | 19.07 - 19.42 |
52-week range | 13.11 - 20.01 |
Volume | |
Avg. volume | 1,012,613 |
Market cap | 3.1B |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | 8.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.92 (9.94%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Harness, the Modern Software Delivery Platform® company, today announced $150 million in financing from Silicon Valley Bank (SVB), a division of First Citizens Bank, and Hercules Capital, Inc. (NYSE: HTGC). The investment will be used strategically to support the expansion of the Harness platform, including the addition of new modules, further integrating generative AI into the platform, and additional investments in the company's go-to-market engine.
SAN MATEO, Calif., May 13, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), will conduct its 2024 Annual Meeting of Stockholders by virtual meeting on Thursday, June 20, 2024 at 9:00 a.m. (Pacific Time). The proxy statement for the meeting was filed on April 23, 2024 and mailed to stockholders of record as of April 19, 2024.
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree C